TYVYT®: Sintilimab Injection

TYVYT®: Sintilimab Injection
Product Description

In China, sintilimab has been approved for seven indications and included in the National Reimbursement Drug List (NRDL) for six indications. In January 2023, TYVYT® has been included in the NRDL for two additional indications including gastric cancer and esophageal cancer. TYVYT® is the first and the only PD-1 inhibitor for gastric cancer in the NRDL, as well as the only PD-1 inhibitor for the first-line treatment of five high-incidence cancer types in the NRDL.

Read more Show less

Altruist Biologics

  • US
  • 2023
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Contract Service
Primary activities
Biopharmaceutical
Contract Manufacturer
Regulatory Affairs
View company profile
Categories
more categories Show less

Altruist Biologics

  • US
  • 2023
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Contract Service
Primary activities
Biopharmaceutical
Contract Manufacturer
Regulatory Affairs
View company profile

More Products from Altruist Biologics (4)

  • BYVASDA®: Bevacizumab Injection

    Product BYVASDA®: Bevacizumab Injection

    Received NMPA marketing approval on Jun 19, 2020 Approved for advanced non-small cell lung cancer and metastatic colorectal cancer, adult recurrent glioblastoma, hepatocellular carcinoma, cervical cancer, ovarian cancer. A total of 8 indications have been approved and included in the NRDL
  • HALPRYZA®: Rituximab Injection

    Product HALPRYZA®: Rituximab Injection

    Received NMPA marketing approval on September, 2020 Approved for Diffuse large b cell lymphoma、Follicular lymphoma、Chronic lymphocytic leukemia HALPRYZA® has been approved in China for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, all of which are included in the NRDL.
  • SINTBILO® :Tafolecimab Injection

    Product SINTBILO® :Tafolecimab Injection

    In Aug 2023,SINTBILO® (tafolecimab injection) is approved by China's NMPA for the treatment of adult patients with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia. Tafolecimab has the advantage of a longer dosing interval compare...
  • SULINNO®: Adalimumab Injection

    Product SULINNO®: Adalimumab Injection

    Received NMPA marketing approval on August, 2020 Approved for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, and polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, non-infectious uveitis. A total of eight approved indications have been included in the NRDL